EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Phenomenon of Thrombotic Microangiopathy in Cancer Patients

Alexander Vorobev iD, Victoria Bitsadze, Fidan Yagubova, Jamilya Khizroeva iD, Antonina Solopova, Maria Tretyakova, Nilufar Gashimova iD, Kristina Grigoreva, Sabina Einullaeva iD, Maria Drozhzhina iD, Aygun Hajiyeva, Emilia Khalilulina und 8 weitere

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25169055 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Alexander Vorobev und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics, Gynecology and Perinatal Medicine, I.M. Sechenov First Moscow State Medical University (Sechenov University), Trubetskaya S…. Hauptthemen laut MEDLINE: Neoplasms, Purpura, Thrombotic Thrombocytopenic, Hemolytic-Uremic Syndrome, COVID-19. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Thrombotic microangiopathy (TMA) encompasses a range of disorders characterized by blood clotting in small blood vessels, leading to organ damage. It can manifest as various syndromes, including thrombotic thrombocytopenic purpura (TTP), hemolytic-uremic syndrome (HUS), and others, each with distinct causes and pathophysiology. Thrombo-inflammation plays a significant role in TMA pathogenesis: inflammatory mediators induce endothelial injury and activation of platelet and coagulation cascade, contributing to microvascular thrombosis. Primary TMA, such as TTP, is primarily caused by deficient ADAMTS13 metalloproteinase activity, either due to antibody-mediated inhibition or intrinsic enzyme synthesis defects. In cancer patients, a significant reduction in ADAMTS13 levels and a corresponding increase in VWF levels is observed. Chemotherapy further decreased ADAMTS13 levels and increased VWF levels, leading to an elevated VWF/ADAMTS13 ratio and increased thrombotic risk. Drug-induced TMA (DITMA) can result from immune-mediated or non-immune-mediated mechanisms. Severe cases of COVID-19 may lead to a convergence of syndromes, including disseminated intravascular coagulation (DIC), systemic inflammatory response syndrome (SIRS), and TMA. Treatment of TMA involves identifying the underlying cause, implementing therapies to inhibit complement activation, and providing supportive care to manage complications. Plasmapheresis may be beneficial in conditions like TTP. Prompt diagnosis and treatment are crucial to prevent serious complications and improve outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsPurpura, Thrombotic ThrombocytopenicHemolytic-Uremic SyndromeCOVID-19Disseminated Intravascular CoagulationSystemic Inflammatory Response Syndromevon Willebrand FactorPlasmapheresisHumansAntineoplastic AgentsADAMTS13 ProteinSeverity of Illness Index

Stichwörter der Autor:innen

ADAMTS13COVID-19cancer patientschemotherapy-induced TMAdrug-induced TMAmicroangiopathic hemolytic anemiathrombo-inflammationthrombotic microangiopathythrombotic thrombocytopenic purpura

Substanzen

ADAMTS13 protein, humanvon Willebrand FactorAntineoplastic AgentsADAMTS13 Protein

Autor:innen und Institutionen

  • Department of Obstetrics, Gynecology and Perinatal Medicine, I.M. Sechenov First Moscow State Medical University (Sechenov University), Trubetskaya Str. 8-2, 119991 Moscow, Russia.
  • Faculty of General Medicine, Russian University of Medicine, 4th Dolgorukovskaya Str., 127006 Moscow, Russia.
  • Faculty of General Medicine, I.M. Sechenov First State Moscow Medical University Baku Branch, Huseyn Javid, Yasamal, Baku AZ1141, Azerbaijan.
  • Faculty of General Medicine, Pirogov Russian National Research Medical University, Ulitsa Ostrovityanova 1, 117997 Moscow, Russia.
  • Center of Pathology of Pregnancy and Hemostasis «Medlabi», 340112 Tbilisi, Georgia.
  • Moscow's Region Odintsovo Maternity Hospital, 143003 Odintsovo, Russia.

ORCID-Profile: Alexander Vorobev, Jamilya Khizroeva, Nilufar Gashimova, Sabina Einullaeva, Maria Drozhzhina, Alexander Cherepanov, Nart Kuneshko, Jean-Christophe Gris, Cihan Ay

Zitieren

APA

Vorobev, A., Bitsadze, V., Yagubova, F., Khizroeva, J., Solopova, A., Tretyakova, M., Gashimova, N., Grigoreva, K., Einullaeva, S., Drozhzhina, M., Hajiyeva, A., Khalilulina, E., Cherepanov, A., Kapanadze, D., Egorova, E., Kuneshko, N., Gris, J. C., Elalamy, I., Ay, C., & Makatsariya, A. (2024). The Phenomenon of Thrombotic Microangiopathy in Cancer Patients. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25169055

Vancouver

Vorobev A, Bitsadze V, Yagubova F, Khizroeva J, Solopova A, Tretyakova M, et al. The Phenomenon of Thrombotic Microangiopathy in Cancer Patients. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25169055

BibTeX
@article{Vorobev2024,
  author = {Vorobev, Alexander and Bitsadze, Victoria and Yagubova, Fidan and Khizroeva, Jamilya and Solopova, Antonina and Tretyakova, Maria and Gashimova, Nilufar and Grigoreva, Kristina and Einullaeva, Sabina and Drozhzhina, Maria and Hajiyeva, Aygun and Khalilulina, Emilia and Cherepanov, Alexander and Kapanadze, Daredzhan and Egorova, Elena and Kuneshko, Nart and Gris, Jean-Christophe and Elalamy, Ismail and Ay, Cihan and Makatsariya, Alexander},
  title = {The Phenomenon of Thrombotic Microangiopathy in Cancer Patients},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25169055}
}
Kostenlos starten →